ScinoPharm Taiwan 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Susan Lu

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.8yrs
CEO 소유권	n/a
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 17

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Apr 04

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Mar 14

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

Feb 21

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Nov 23

CEO

Susan Lu

3.8yrs

테뉴어

Ms. Li-An Lu, also known as Susan, is Director of SciAnda (Changshu) Pharmaceutical, Ltd. from June 14, 2024. She serves as President and Chief Executive Officer at ScinoPharm Taiwan, Ltd.since 2021. She...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chih-Hsien Lo	Chairman & General Chief Strategy Officer	14.3yrs	데이터 없음	데이터 없음
Li-An Lu	President & CEO	3.8yrs	데이터 없음	데이터 없음
Chih-Hui Lin	Acting Financial Off.	14.4yrs	데이터 없음	데이터 없음
Ling-Hsiao Lien	Vice-President of Marketing	4.3yrs	데이터 없음	데이터 없음
Li-Chiao Chang	VP of R&D Division and Chief Scientific Officer	no data	데이터 없음	0% NT$ 0
Jason Chen	Director of Human Resources & Admin	3.4yrs	데이터 없음	데이터 없음
Shun Yang Lin	Director of Corporate Development	no data	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

경험이 풍부한 관리: 1789 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chih-Hsien Lo	Chairman & General Chief Strategy Officer	14.3yrs	데이터 없음	데이터 없음
Po-Ming Hou	Representative Director	8yrs	데이터 없음	데이터 없음
Fu-Jung Lai	Representative Director	6.1yrs	데이터 없음	데이터 없음
Shiow-Ling Kao	Representative Director	14.3yrs	데이터 없음	데이터 없음
Chiou-Ru Shih	Representative Director	14.3yrs	데이터 없음	데이터 없음
Tsung-Ping Wu	Representative Director	9.4yrs	데이터 없음	데이터 없음
Jia-Horng Guo	Representative Director	7.3yrs	데이터 없음	데이터 없음
Li-Tzong Chen	Independent Director	6.4yrs	데이터 없음	데이터 없음
Ming-Chuan Hsieh	Representative Director	6.4yrs	데이터 없음	데이터 없음
Ya-Po Yang	Representative Director	6.4yrs	데이터 없음	데이터 없음
Wen-Chang Chang	Independent Director	6.4yrs	데이터 없음	데이터 없음
Lewis Lee	Independent Director	3.8yrs	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

경험이 풍부한 이사회: 1789 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

ScinoPharm Taiwan 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Scinopharm Taiwan, Ltd. Elects Lai-Shou Su as Independent Director

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 28, 2024

ScinoPharm Taiwan, Ltd Announces Executive Changes

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 30, 2022

ScinoPharm Taiwan, Ltd., Annual General Meeting, Jun 29, 2021

Recent updates

Third quarter 2024 earnings released: EPS: NT$0.03 (vs NT$0.039 in 3Q 2023)

ScinoPharm Taiwan, Ltd. to Report Q3, 2024 Results on Nov 04, 2024

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.072 in 2Q 2023)

ScinoPharm Taiwan, Ltd. to Report Q2, 2024 Results on Aug 05, 2024

ScinoPharm Taiwan's (TWSE:1789) Shareholders Will Receive A Smaller Dividend Than Last Year

Dividend reduced to NT$0.30

New minor risk - Earnings quality

Scinopharm Taiwan, Ltd. Elects Lai-Shou Su as Independent Director

First quarter 2024 earnings released: EPS: NT$0.18 (vs NT$0.053 in 1Q 2023)

ScinoPharm Taiwan, Ltd. to Report Q1, 2024 Results on May 06, 2024

Now 22% undervalued

Now 20% undervalued

Full year 2023 earnings: EPS and revenues exceed analyst expectations

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 28, 2024

Consensus revenue estimates fall by 11%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: NT$0.07 (vs NT$0.14 in 2Q 2022)

Upcoming dividend of NT$0.36 per share at 1.2% yield

ScinoPharm Taiwan, Ltd. Approves Cash Dividend for 2022, Payable on July 28, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$0.48 per share

Consensus EPS estimates increase by 13%

Scinopharm Taiwan, Ltd Approves Cash Dividend, Payable August 2, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

ScinoPharm Taiwan, Ltd Announces Executive Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

ScinoPharm Taiwan, Ltd., Annual General Meeting, May 30, 2022

Third quarter 2021 earnings released: EPS NT$0.01 (vs NT$0.097 in 3Q 2020)

Upcoming dividend of NT$0.50 per share

Second quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.20 in 2Q 2020)

Consensus EPS estimates increase to NT$0.61

First quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.045 in 1Q 2020)

Investors In ScinoPharm Taiwan, Ltd. (TPE:1789) Should Consider This, First

Full year 2020 earnings released: EPS NT$0.36 (vs NT$0.27 in FY 2019)

ScinoPharm Taiwan, Ltd., Annual General Meeting, Jun 29, 2021

A Look At The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

Weak Financial Prospects Seem To Be Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789) Stock

New 90-day low: NT$24.15

ScinoPharm Taiwan's (TPE:1789) Shareholders Are Down 45% On Their Shares

New 90-day low: NT$27.00

We Think ScinoPharm Taiwan (TPE:1789) Can Manage Its Debt With Ease

Estimating The Intrinsic Value Of ScinoPharm Taiwan, Ltd. (TPE:1789)

New 90-day low: NT$27.95

Are Poor Financial Prospects Dragging Down ScinoPharm Taiwan, Ltd. (TPE:1789 Stock?

Revenue and earnings miss expectations

Third quarter 2020 earnings released: EPS NT$0.10

New 90-day low: NT$29.40

Second-quarter earnings released: Revenue and earnings beat expectations

First half earnings released

New 90-day low: NT$30.15

First half earnings released

Upcoming Dividend of NT$0.27 Per Share

CEO

테뉴어

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간